According to Frost & Sullivan, over the next decade, there will be a shift in digital pathology and artificial intelligence (AI) applications from the pharmaceutical sector to clinical diagnostics. Once they are established as primary and secondary diagnostic tools, clinicians will be able to decrease turnaround time, prioritize critical cases, and improve overall patient outcomes. However, for AI tools to gain regulatory approval for primary diagnosis in digital pathology, it is imperative to adopt a parallel workflow to showcase the superior benefits of pathology diagnoses that amass data.
“AI has the potential to analyze big data and find patterns and insights that could enhance patient outcomes in the field of pathology,” said Frost & Sullivan Analyst. “It can serve as a supplementary or a validation tool in imaging analytics for pathologists, and help process more slides in a shorter duration.
“So far, AI-based medical diagnostic tools like OsteoDetect have already been approved for use by the FDA for the detection of distal radius fracture. Furthermore, AI-powered tools can better identify skin lesions and the presence of invasive breast cancer,” said Frost & Sullivan Analyst.
“Hospitals and diagnostic labs will be the largest adopters of digital pathology over the next decade,” said the analyst. “Technology innovators can ensure greater commercialization by focusing on improving cost optimization for end users through pay-per-use or Software-as-a-Service (SaaS) models,” said Frost & Sullivan Analyst.
“Additionally, they could map service gaps, expand product portfolios, and use the information obtained from clinical data to develop cutting-edge solutions,” said Frost & Sullivan Analyst.